Corcept Therapeutics

The company operates in the healthcare and pharmaceutical market, serving patients with conditions such as Cushing's syndrome, a disorder caused by excessive cortisol. Corcept's flagship product, Korlym (mifepristone), received FDA approval in 2012 and is the first approved treatment for hypercortisolism in patients with Cushing's syndrome.

Corcept's business model revolves around the discovery, development, and commercialization of proprietary cortisol modulators. The company invests heavily in research and development (R&D) to create new molecules that can effectively modulate cortisol activity. To date, Corcept has discovered over 1,000 selective cortisol modulators. The company generates revenue primarily through the sale of its approved drug, Korlym, and aims to expand its product portfolio with additional treatments currently in the pipeline.

Corcept also supports medical and patient education by funding independent grants and providing educational resources to healthcare professionals and patients. This commitment to education helps improve patient care and fosters a better understanding of cortisol-related conditions.

In summary, Corcept Therapeutics is a leader in the field of cortisol modulation, dedicated to developing innovative treatments for serious medical conditions related to cortisol imbalance. The company serves patients with Cushing's syndrome and other cortisol-related disorders, operating within the healthcare and pharmaceutical market. Its business model focuses on R&D and commercialization of proprietary cortisol modulators, with revenue generated from drug sales and educational initiatives.